Danish pharmaceuticals Novo Nordisk announced the appointment of Yiannis Mallis as the new director of this laboratory in Mexico, who said that the impulse of new generation therapies will continue for the treatment of diabetes and other chronic diseases.
The announcement was released in this city, where this weekend the third edition “Meeting of Administrative Experts in Diabetes 2017” was held, which congregated more than 120 representatives from different government institutions related to public health expenditure in Mexico.
The symposium organized by Novo Nordisk Mexico has the objective of promoting change in diabetes care with the improvement in the processes of detection, prevention and treatment of this disease, in order to improve the life expectancy in patients.
During the event, topics such as the treatment of this condition with biocomparable medications, costs and results were addressed, where the importance of handling them with care and surveillance was presented, because if they are not evaluated they can properly represent a complication to reduce incidence ratesof diabetes in the country.
In addition, educational workshops were given at the meeting where attendees were able to experience what it is like to live with diabetes, through the practice of insulinization.
The complications associated with this condition between which stand out: neuropathies, diabetic retinopathy and amputations, among others, were also explained, in order to sensitize those present about the importance of medical care on time and specialized.
